Home
>
US Stocks
>
Fate Therapeutics Inc

Fate Therapeutics Inc (FATE)

$5.04

+0.08

(+1.61%)▲

Market is closed - opens 7 PM, 01 Jun 2023

Insights on Fate Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 14.98M → 58.98M (in $), with an average increase of 45.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -83.56M → -9.17M (in $), with an average increase of 281.5% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 43.0% return, outperforming this stock by 121.5%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 23.4% return, outperforming this stock by 108.1%

Performance

  • $4.90
    $5.23
    $5.04
    downward going graph

    2.78%

    Downside

    Day's Volatility :6.31%

    Upside

    3.63%

    downward going graph
  • $4.02
    $37.13
    $5.04
    downward going graph

    20.24%

    Downside

    52 Weeks Volatility :89.17%

    Upside

    86.43%

    downward going graph

Returns

PeriodFate Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-18.95%
-0.3%
-6.7%
6 Months
-76.18%
-8.8%
-6.2%
1 Year
-78.53%
-4.2%
-5.1%
3 Years
-84.34%
23.0%
26.9%

Highlights

Market Capitalization
504.7M
Book Value
$4.86
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.32
PEG Ratio
0.0
Wall Street Target Price
8.16
Profit Margin
-171.64%
Operating Margin TTM
-191.8%
Return On Assets TTM
-22.04%
Return On Equity TTM
-42.29%
Revenue TTM
136.9M
Revenue Per Share TTM
1.41
Quarterly Revenue Growth YOY
220.29999999999998%
Gross Profit TTM
-224.2M
EBITDA
-247.3M
Diluted Eps TTM
-2.32
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.86
EPS Estimate Next Year
-2.0
EPS Estimate Current Quarter
-0.62
EPS Estimate Next Quarter
-0.62

Analyst Recommendation

Hold
    41%Buy
    51%Hold
    6%Sell
Based on 29 Wall street analysts offering stock ratings for Fate Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 29 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
15
16
16
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 61.9%

Current $5.04
Target $8.16

Company Financials

FY17Y/Y Change
Revenue
4.1M
↓ 6.72%
Net Income
-43.0M
↑ 28.36%
Net Profit Margin
-1.0K%
↓ 285.93%
FY18Y/Y Change
Revenue
4.7M
↑ 15.44%
Net Income
-66.6M
↑ 55.05%
Net Profit Margin
-1.4K%
↓ 358.94%
FY19Y/Y Change
Revenue
10.7M
↑ 125.32%
Net Income
-98.1M
↑ 47.38%
Net Profit Margin
-919.0%
↑ 486.02%
FY20Y/Y Change
Revenue
31.4M
↑ 194.33%
Net Income
-173.4M
↑ 76.66%
Net Profit Margin
-551.59%
↑ 367.41%
FY21Y/Y Change
Revenue
55.8M
↑ 77.66%
Net Income
-212.2M
↑ 22.36%
Net Profit Margin
-379.89%
↑ 171.7%
FY22Y/Y Change
Revenue
96.3M
↑ 72.44%
Net Income
-281.7M
↑ 32.79%
Net Profit Margin
-292.55%
↑ 87.34%
Q4 FY21Q/Q Change
Revenue
17.1M
↑ 19.99%
Net Income
-68.6M
↑ 58.45%
Net Profit Margin
-402.02%
↓ 97.57%
Q1 FY22Q/Q Change
Revenue
18.4M
↑ 7.88%
Net Income
-65.7M
↓ 4.27%
Net Profit Margin
-356.74%
↑ 45.28%
Q2 FY22Q/Q Change
Revenue
18.5M
↑ 0.73%
Net Income
-76.1M
↑ 15.85%
Net Profit Margin
-410.29%
↓ 53.55%
Q3 FY22Q/Q Change
Revenue
15.0M
↓ 19.24%
Net Income
-83.6M
↑ 9.8%
Net Profit Margin
-557.79%
↓ 147.5%
Q4 FY22Q/Q Change
Revenue
44.4M
↑ 196.08%
Net Income
-56.4M
↓ 32.55%
Net Profit Margin
-127.07%
↑ 430.72%
Q1 FY23Q/Q Change
Revenue
59.0M
↑ 32.97%
Net Income
-9.2M
↓ 83.73%
Net Profit Margin
-15.55%
↑ 111.52%
FY17Y/Y Change
Total Assets
105.3M
↑ 10.78%
Total Liabilities
28.1M
↑ 28.36%
FY18Y/Y Change
Total Assets
213.0M
↑ 102.32%
Total Liabilities
52.6M
↑ 87.04%
FY19Y/Y Change
Total Assets
302.3M
↑ 41.89%
Total Liabilities
57.5M
↑ 9.43%
FY20Y/Y Change
Total Assets
622.5M
↑ 105.92%
Total Liabilities
238.0M
↑ 313.8%
FY21Y/Y Change
Total Assets
921.5M
↑ 48.04%
Total Liabilities
242.6M
↑ 1.93%
FY22Y/Y Change
Total Assets
705.6M
↓ 23.43%
Total Liabilities
221.6M
↓ 8.65%
Q4 FY21Q/Q Change
Total Assets
921.5M
↓ 6.41%
Total Liabilities
242.6M
↓ 4.57%
Q1 FY22Q/Q Change
Total Assets
858.4M
↓ 6.84%
Total Liabilities
225.0M
↓ 7.26%
Q2 FY22Q/Q Change
Total Assets
807.1M
↓ 5.98%
Total Liabilities
226.6M
↑ 0.7%
Q3 FY22Q/Q Change
Total Assets
749.3M
↓ 7.15%
Total Liabilities
231.3M
↑ 2.11%
Q4 FY22Q/Q Change
Total Assets
705.6M
↓ 5.84%
Total Liabilities
221.6M
↓ 4.2%
Q1 FY23Q/Q Change
Total Assets
630.3M
↓ 10.66%
Total Liabilities
152.9M
↓ 31.02%
FY17Y/Y Change
Operating Cash Flow
-36.9M
↑ 23.75%
Investing Cash Flow
-10.2M
↑ 147.84%
Financing Cash Flow
47.4M
↓ 17.83%
FY18Y/Y Change
Operating Cash Flow
-38.7M
↑ 4.73%
Investing Cash Flow
-463.0K
↓ 95.46%
Financing Cash Flow
140.8M
↑ 196.73%
FY19Y/Y Change
Operating Cash Flow
-83.2M
↑ 115.2%
Investing Cash Flow
-157.5M
↑ 33907.13%
Financing Cash Flow
149.9M
↑ 6.5%
FY20Y/Y Change
Operating Cash Flow
-39.2M
↓ 52.84%
Investing Cash Flow
-161.1M
↑ 2.3%
Financing Cash Flow
282.8M
↑ 88.65%
FY21Y/Y Change
Operating Cash Flow
-162.9M
↑ 315.18%
Investing Cash Flow
-324.0M
↑ 101.16%
Financing Cash Flow
453.1M
↑ 60.21%
Q4 FY21Q/Q Change
Operating Cash Flow
-70.3M
↑ 110.62%
Investing Cash Flow
71.3M
↓ 8.57%
Financing Cash Flow
3.4M
↓ 56.96%
Q1 FY22Q/Q Change
Operating Cash Flow
-64.6M
↓ 8.08%
Investing Cash Flow
-7.0M
↓ 109.86%
Financing Cash Flow
2.8M
↓ 18.17%
Q2 FY22Q/Q Change
Operating Cash Flow
-53.2M
↓ 17.73%
Investing Cash Flow
40.3M
↓ 673.4%
Financing Cash Flow
3.4M
↑ 21.77%
Q3 FY22Q/Q Change
Operating Cash Flow
-55.0M
↑ 3.55%
Investing Cash Flow
80.4M
↑ 99.51%
Financing Cash Flow
1.5M
↓ 56.34%

Technicals Summary

Sell

Neutral

Buy

Fate Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Fate Therapeutics Inc
Fate Therapeutics Inc
-22.01%
-76.18%
-78.53%
-84.34%
-54.7%
Moderna, Inc.
Moderna, Inc.
-3.38%
-26.73%
-11.31%
107.29%
592.96%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.68%
-3.07%
9.61%
21.54%
142.61%
Seagen, Inc.
Seagen, Inc.
-2.59%
59.82%
42.99%
22.0%
220.73%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.71%
2.81%
21.09%
13.49%
111.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Fate Therapeutics Inc
Fate Therapeutics Inc
NA
NA
0.0
-1.86
-0.42
-0.22
0.0
4.86
Moderna, Inc.
Moderna, Inc.
11.22
11.22
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.53
26.53
0.41
13.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Fate Therapeutics Inc
Fate Therapeutics Inc
Hold
$504.7M
-54.7%
NA
-171.64%
Moderna, Inc.
Moderna, Inc.
Buy
$48.1B
592.96%
11.22
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
142.61%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.3B
220.73%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.0B
111.23%
26.53
35.4%

Institutional Holdings

  • State Street Corporation

    15.07%

  • Redmile Group, LLC

    13.17%

  • Vanguard Group Inc

    11.14%

  • BlackRock Inc

    9.89%

  • Bellevue Group AG

    4.94%

  • Johnson & Johnson

    3.43%

Corporate Announcements

  • Fate Therapeutics Inc Earnings

    Fate Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.

Organization
Fate Therapeutics Inc
Employees
551
CEO
Mr. J. Scott Wolchko
Industry
Health Technology

Discover More

FAQs